SCHEMBL14940925

SCHEMBL14940925

CC1C(=O)Nc2cnc(Cl)nc2N1c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
BRPF1 P55201 1/20 0.35
CREBBP Q92793 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
CASP1 P29466 2/20 0.34
HSD17B10 Q99714 2/20 0.34
POLB P06746 1/20 0.34
GAA P10253 2/20 0.33
G6PD P11413 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 2/20 0.32
GSK3B P49841 2/20 0.32
GSK3A P49840 1/20 0.32
LMNA P02545 1/20 0.32
ATM Q13315 1/20 0.32
TSHR P16473 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KIF11 P52732 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5936823 0.84 MAPK1 (0.42) MAPTALDH1A1HPGDCASP1HSD17B10
SCHEMBL15824039 0.82 BRPF1 (0.36) BRPF1CREBBPALDH1A1HPGDCASP1
SCHEMBL3670859 0.79 GAA (0.42) MAPTALDH1A1HPGDPOLBGAA
SCHEMBL21491922 0.78 RPS6KA3 (0.36) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL21261609 0.78 RPS6KA3 (0.36) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL5815549 0.75 GSK3B (0.64) GSK3BGSK3ARPS6KA3
SCHEMBL16390761 0.74 PLK2 (0.44) MAPTPIN1BRD4RPS6KA3HCRTR2
SCHEMBL14952202 0.74 PIN1 (0.39) MAPTALDH1A1HPGDPOLBGAA
SCHEMBL5937139 0.74 MAPK1 (0.38) MAPTALDH1A1HPGDCASP1HSD17B10
SCHEMBL5937040 0.72 MAPK1 (0.36) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 US disclosed
EP-2776444-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC (US) 2014-09-17 EP disclosed
WO-2013071217-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC (US) 2013-05-16 WO disclosed
WO-2013071217-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC (US) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315911-A1 DIHYDROPTERIDINONES DHPS, DHODH, HYPK MAPT 2490/4885BRPF1 4063/4885CREBBP 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.